News Reader.info

ABSTRACT The present study compares the prognostic potential of tumour grade and DNA ploidy status in patients with advanced-stage prostatic cancer. Two outcome groups were selected on the

basis of time to progression and survival after orchiectomy. A poor-outcome group consisted of 32 therapy-resistant patients who experienced disease progression during the first year after

orchiectomy and subsequently death due to prostatic cancer during the following year. A good-outcome group consisted of 27 therapy-responsive patients who showed disease regression and no

signs of progression during a 3 year follow-up. The primary tumours were graded twice according to WHO and Gleason classification systems by two pathologists. Final agreement between the

pathologists was obtained after a consensus meeting. The analysis revealed no prognostic importance of the two histological classification systems (P = 0.62 and P = 0.70) and disclosed weak

inter- and intra-observer reproducibility (kappa < 0.70). DNA ploidy analyses were performed by image cytometry on formalin-fixed, paraffin-embedded samples of the primary tumours.

Overall, 48% of the tumours were diploid, 20% tetraploid and 32% anueploid. DNA ploidy status did not discriminate between the two outcome groups (P = 0.46). Histological grade and DNA

ploidy showed no prognostic importance in patients with prostatic cancer and skeletal metastases. Access through your institution Buy or subscribe This is a preview of subscription content,

access via your institution ACCESS OPTIONS Access through your institution Subscribe to this journal Receive 24 print issues and online access $259.00 per year only $10.79 per issue Learn

more Buy this article * Purchase on SpringerLink * Instant access to full article PDF Buy now Prices may be subject to local taxes which are calculated during checkout ADDITIONAL ACCESS

OPTIONS: * Log in * Learn about institutional subscriptions * Read our FAQs * Contact customer support SIMILAR CONTENT BEING VIEWED BY OTHERS DNA PLOIDY AND PTEN AS BIOMARKERS FOR PREDICTING

AGGRESSIVE DISEASE IN PROSTATE CANCER PATIENTS UNDER ACTIVE SURVEILLANCE Article Open access 03 July 2024 ANALYSIS OF THE SURGICAL APPROACH IN PROSTATE CANCER STAGING: RESULTS FROM THE

SURVEILLANCE, EPIDEMIOLOGY AND END RESULTS PROGRAM Article Open access 19 June 2023 SATB1, GENOMIC INSTABILITY AND GLEASON GRADING CONSTITUTE A NOVEL RISK SCORE FOR PROSTATE CANCER Article

Open access 27 December 2021 AUTHOR INFORMATION AUTHORS AND AFFILIATIONS * Department of Pathology, Norwegian Radium Hospital, Oslo T Jørgensen Authors * T Jørgensen View author publications

You can also search for this author inPubMed Google Scholar * K Yogesan View author publications You can also search for this author inPubMed Google Scholar * F Skjørten View author

publications You can also search for this author inPubMed Google Scholar * A Berner View author publications You can also search for this author inPubMed Google Scholar * KJ Tveter View

author publications You can also search for this author inPubMed Google Scholar * HE Danielsen View author publications You can also search for this author inPubMed Google Scholar RIGHTS AND

PERMISSIONS Reprints and permissions ABOUT THIS ARTICLE CITE THIS ARTICLE Jørgensen, T., Yogesan, K., Skjørten, F. _et al._ Histopathological grading and DNA ploidy as prognostic markers in

metastatic prostatic cancer. _Br J Cancer_ 71, 1055–1060 (1995). https://doi.org/10.1038/bjc.1995.203 Download citation * Issue Date: 01 May 1995 * DOI: https://doi.org/10.1038/bjc.1995.203

SHARE THIS ARTICLE Anyone you share the following link with will be able to read this content: Get shareable link Sorry, a shareable link is not currently available for this article. Copy

to clipboard Provided by the Springer Nature SharedIt content-sharing initiative